Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation (DELEXIS) of MPH HCl, on Post-waking, Early Morning Function in Children Aged 6-12 With ADHD

NCT02520388 is registered in ClinicalTrials.gov with Ironshore Pharmaceuticals and Development, Inc as lead sponsor.

NCT NCT02520388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph 3 Multicenter DBRCT Parallel Group Study to Evaluate Safety & Efficacy of Evening-dosed HLD200, a Novel Delayed & Extended Release Formulation (DELEXIS) of MPH HCl, on Post-waking, Early Morning Function in Children Aged 6-12 With ADHD
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2015
Completion date
May 31, 2016
Enrollment
163 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder